vimarsana.com

Latest Breaking News On - Andrew craig miller - Page 1 : vimarsana.com

Karuna Therapeutics, Inc (NASDAQ:KRTX) Shares Bought by China Universal Asset Management Co Ltd

China Universal Asset Management Co. Ltd. boosted its holdings in shares of Karuna Therapeutics, Inc. (NASDAQ:KRTX – Free Report) by 34.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 468 shares of the company’s stock after acquiring an additional […]

EFG Asset Management North America Corp Increases Position in Karuna Therapeutics, Inc (NASDAQ:KRTX)

EFG Asset Management North America Corp. raised its position in Karuna Therapeutics, Inc. (NASDAQ:KRTX – Free Report) by 16.8% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 6,858 shares of the company’s stock after purchasing an additional 987 shares during […]

Karuna Therapeutics, Inc (NASDAQ:KRTX) Receives $275 44 Consensus Target Price from Brokerages

Shares of Karuna Therapeutics, Inc. (NASDAQ:KRTX – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the fifteen brokerages that are covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The average 1 year […]

FY2025 EPS Estimates for Karuna Therapeutics, Inc (NASDAQ:KRTX) Lowered by Analyst

Karuna Therapeutics, Inc. (NASDAQ:KRTX – Get Rating) – Investment analysts at Zacks Research lowered their FY2025 EPS estimates for Karuna Therapeutics in a research note issued on Thursday, June 15th. Zacks Research analyst S. Ganoria now forecasts that the company will earn ($5.07) per share for the year, down from their previous forecast of ($4.81). […]

Brokerages Set Karuna Therapeutics, Inc (NASDAQ:KRTX) PT at $275 44

Shares of Karuna Therapeutics, Inc. (NASDAQ:KRTX – Get Rating) have been given a consensus recommendation of “Moderate Buy” by the fifteen ratings firms that are covering the firm, Marketbeat reports. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. The average 12-month price […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.